- In December 2023, Genentech announced positive long-term follow-up results from the pivotal Phase III KATHERINE study involving individuals with HER2-positive early-stage breast cancer (eBC) who had residual invasive disease after receiving neoadjuvant (pre-surgery) therapy. The study showed a statistically significant and clinically meaningful improvement in overall survival (OS)—a key secondary endpoint—with adjuvant (post-surgery) treatment using Kadcyla (ado-trastuzumab emtansine) compared to Herceptin
- In May 2021, Indian generics manufacturer Zydus Cadila (Zydus) announced the launch of Ujvira, its ‘similar biologic’ version of trastuzumab emtansine, in India. According to Zydus, this launch represents the world’s first biosimilar antibody-drug conjugate (ADC) of trastuzumab emtansine
